covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Acidosis láctica por metformina
Journal Information
Vol. 54. Issue 6.
Pages 325-327 (June 2007)
Share
Share
Download PDF
More article options
Vol. 54. Issue 6.
Pages 325-327 (June 2007)
Notas clínicas
Full text access
Acidosis láctica por metformina
Metformin-induced lactic acidosis
Visits
93052
Laura de la Maza Pereg
Corresponding author
alonsomaza@ono.com

Correspondencia: Dra. L. de la Maza Pereg. Sección de Endocrinología y Nutrición. Hospital General Yagüe. Avda. del Cid, 96. 09005 Burgos. España.
, Víctor Manuel García Hierro, Pilar Álvarez Baños, Javier Pi Barrio, Luis Castillo López, Enrique Ruiz Pérez
Sección de Endocrinología y Nutrición. Hospital General Yagüe. Burgos. España
This item has received
Article information

La acidosis láctica es un efecto secundario de la metformina poco frecuente, que es más probable que se produzca en pacientes con ciertas condiciones predisponentes.

Presentamos el caso de un paciente con hipertensión arterial tratada con indapamida y captopril y diabetes mellitus tipo 2 tratada con insulina y metformina con función renal previa normal, que tras toma de antiinflamatorios no esteroideos presenta cuadro de vómitos, dolor abdominal, diarrea, oliguria y acidosis láctica.

En la analítica al ingreso, se objetivó urea a 227mg/dl, creatinina a 13,2mg/dl, pH 6,98, bicarbonato a 7,1mmol/l y ácido láctico a 105,4mg/dl (normal hasta 19,8mg/dl). Tras tratamiento con dos sesiones de hemodiálisis, el paciente evoluciona favorablemente, aunque al alta persiste la insuficiencia renal.

La acidosis láctica es una seria complicación del tratamiento con metformina que es más frecuente en casos de insuficiencia renal y otros procesos intercurrentes.

Palabras clave:
Metformina
Acidosis láctica
Insuficiencia renal

Lactic acidosis is an uncommon side effect of metformin use, which is more likely to arise in patients with certain predisposing factors.

We present the case of a patient with hypertension treated with indapamide and captopril and type 2 diabetes mellitus treated with insulin and metformin.

Previous renal function was normal. After taking non-steroidal anti-inflammatory drugs, the patient developed vomiting, abdominal pain, diarrhea, oliguria, and lactic acidosis.

Tests on admission showed urea 227mg/dl, creatinine 13.2mg/dl, pH 6.98, bicarbonate 7.1mmol/l, and lactic acid 105.4mg/dl (normal below 19.8mg/dl). After two hemodialysis sessions, the patient improved, although kidney failure persisted after discharge.

Lactic acidosis is a serious complication of metformin therapy and is more frequent in patients with kidney failure and other intercurrent complaints.

Key words:
Metformin
Lactic acidosis
Kidney failure
Full text is only aviable in PDF
Bibliografía
[1.]
S.C. Gan, J. Barr, Al. Arrieff, R.G. Pearl.
Biguanide associated lactic acidosis. Case report and review of the literature.
Arch Intern Med, 152 (1992), pp. 2333-2336
[2.]
M. Stang, D.K. Wysowski, D. Butler Jones.
Incidende of lactic acidosis in metformin users.
Diabetes Care, 22 (1999), pp. 925
[3.]
T.V. Sulkin, D. Bosman, A.J. Krentz.
Contraindications to metformin therapy in patients with NIDDM.
Diabetes Care, 20 (1997), pp. 925
[4.]
C.J. Bailey.
Biguanides and NIDDM.
Diabetes Care, 15 (1992), pp. 755
[5.]
C.J. Bailey, R.C. Turner.
Metformin.
N Engl J Med, 334 (1996), pp. 574
[6.]
M. Stumvoll, N. Nurijhan, G. Periello.
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
N Engl J Med, 333 (1995), pp. 550
[7.]
G. Schafer.
Biguanides: A review of history, pharmacodynamics and therapy.
Diab Metab, 9 (1983), pp. 148
[8.]
S. Salpeter, E. Greyber, G. Pasternak, E. Salpeter.
Risk of fatal and non fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Systematic review and meta-analysis.
Arch Intern Med, 163 (2003), pp. 2594-2602
[9.]
C.R. Sirtori, C. Pasik.
Re-evaluation of a biguanide: mechanism of action and tolerability.
Pharmacol Res, 30 (1994), pp. 187
[10.]
C. Horlen, R. Malone, B. Dennis, T. Carey.
Frecuency of innapropiate metformin prescriptions.
JAMA, 287 (2002), pp. 2504
[11.]
A.T. Calabrese, K.C. Caley, S.V. Da Pos.
Evaluation of prescribing practices; risk of lactic acidosis with metformin therapy.
Arch Intern Med, 162 (2002), pp. 434
[12.]
D.T. Eurich, S.R. Majumdar, F.A. McAlister, R.T. Tsuyuki, J.A. Johnson.
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
Diabetes Care, 28 (2005), pp. 2345-2351
[13.]
F.A. Masoudi, S.E. Inzucchi, Y. Wang, E.P. Havranek, J.M. Foody, H.M. Krumholz.
Thiazolidinediones, metformina and outcomes in older patients with diabetes and heart failure: an observational study.
Circulation, 111 (2005), pp. 583-590
[14.]
J.D. Lalau, J.M. Race.
Metformin and lactic acidosis in diabetic humans.
Diabetes Obes Metab, 2 (2000), pp. 131-137
[15.]
J.D. Lalau, J.M. Race.
Lactic acidosis in metformin therapy: searching for a link with metformin reports of metformin-associatted lactic acidosis.
Diabetes Obes Metab, 3 (2001), pp. 195-201
[16.]
D. Heaney, A. Majhid, B. Junor.
Bicarbonate haemodialysis as a treatment of metformin overdose.
Nephrol Dial Transplant, 12 (1997), pp. 1046-1047
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos